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INTRODUCTION 
Buccal mucosa is an attractive route for systemic 
delivery of drugs since it is relatively permeable with a 
rich blood supply. A drug can be easily applied and 
localized to the application site, and can be removed 
from there if necessary. Attempt has been made earlier 
to formulate various mucoadhesive buccal devices, 
including tablets, films, patches, disks, strips, 
ointments and gels. Buccal patches are highly flexible 
and thus much more readily tolerated by the patient 
than tablets. Patches also ensure more accurate dosing 
of the drug compared to gels and ointments. 
During the last decade, bioadhesive polymers received 
considerable attention as plat-forms for buccal 
controlled delivery due to their ability to localize the 
dosage form in specific regions to enhance drug 
bioavailability. In the present study, the natural 
bioadhesive polymer chitosan was selected for the 
development of controlled release buccal 
mucoadhesive devices. Chitosan is the N-deacetylated 
product of the polysaccharide chitin . Chitosan is 
gaining increasing importance in the pharmaceutical 
field due to its good biocompatibility, after both 
intravenous and oral administration, and its non-
toxicity and biodegradable. From the technological 
point of view, chitosan has also been demonstrated to 
be a promising matrix carrier for sustained drug 
release and it possesses excellent film-forming 
properties. In spite of this, only a few studies have so 
far been performed on the usefulness of chitosan films 
as drug delivery systems
1
. 
Metoprolol succinate, a non-selective -adrenergic 
blocking agent, has been widely used in the treatment 
of hypertension, angina pectoris and many other 
cardio-vascular disorders
2
. 
The present study was an attempt to develop chitosan-
containing mucoadhesive buccal patches to ensure 
satisfactory release of metoprolol succinate for 
prolonged periods. The influence of 
Polyvinylpyrrolidone K-30 (PVP K-30) and drug 
concentration on the drug release and mucoadhesive 
performance on sheep buccal patches was investigated. 
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ABSTARCT 
Mucoadhesive buccal patches containing metoprolol succinate were prepared using the solvent casting method. Chitosan 
was used as bioadhesive polymer and different ratios of chitosan to PVP K-30 were used. The patches were evaluated for 
their physical characteristics like mass variation, drug content uniformity, folding endurance, ex vivo mucoadhesion 
strength, ex vivo mucoadhesion time, surface pH, in vitro drug release, and in vitro buccal permeation study. Patches 
exhibited controlled release for a period of 8 h. The mechanism of drug release was found to be non-Fickian diffusion and 
followed the first-order kinetics. Incorporation of PVP K-30 generally enhanced the release rate. Swelling index was 
proportional to the concentration of PVP K-30. Optimized patches (F4) showed satisfactory bioadhesive strength of 9.6 ± 
2.0 g, and ex vivo mucoadhesion time of 272 minutes. The surface pH of all patches was between 5.5 and 6.8 and hence 
patches should not cause irritation in the buccal cavity. Patches containing 10 mg of drug had higher bioadhesive strength 
with sustained drug release as compared to patches containing 20 mg of drug. Good correlation was observed between the in 
vitro drug release and in vitro drug permeation with a correlation coefficient of 0.9364. Stability study of optimized patches 
was done in human saliva and it was found that both drug and buccal patches were stable. 
Keywords: Chitosan , Poly-vinyl alcohol, Mucoadhesion, Buccal patch, Metoprolol succinate. 
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MATERIALS AND METHODS 
Metoprolol succinate (99.00% purity) was a gift 
sample from Aarti drug Pvt Ltd., India. Chitosan (180 
cps, 75% deacetylation) was procured from Sigma 
Aldrich, India. PVP K-30 (S. D. Fine Chemicals, 
India) was obtained from a commercial source. All 
other reagents and chemicals used were of analytical 
reagent grade. 
Preparation of mucoadhesive buccal patches 
Patches containing different drug and chitosan 
proportions were prepared by the solvent casting 
method. One gm of chitosan was dissolved in 100 ml 
1.5% (w/v) acetic acid under occasional stirring for 24 
hrs. The resulting viscous chitosan solution was 
filtered through whatman filter paper to remove 
suspended particles. To improve patch performance 
and release characteristics, a water-soluble hydrophilic 
additive, PVP K-30, was added in different 
concentrations. The drug and PVP K-30 were added 
into the chitosan solution under constant stirring. 
Propylene glycol (10%, v/v) was added into the 
solution as plasticizer under constant stirring. This 
viscous solution was left overnight at room 
temperature to ensure a clear, bubble-free solution. 
The solution was poured into a glass petri dish and 
allowed to dry at room temperature till a flexible film 
was formed. Dried films were carefully removed, 
checked for any imperfections or air bubbles and cut 
into patches of 16 mm in diameter, containing 20 mg 
of drug per patch. The patches were packed in 
aluminum foil and stored in an airtight glass container 
to maintain the integrity and elasticity of the patches 
3
. 
Table 1 shows the composition of different buccal 
patches. 
 
Table 1: Composition of chitosan buccal patches of metoprolol Succinate 
 
 
Mass uniformity  
Mass uniformity was tested in 10 different randomly 
selected patches from each batch and patch thickness 
was measured at 5 different randomly selected spots 
using a screw gauge
4
. 
Folding endurance 
Folding endurance of the patches was determined by 
repeatedly folding one patch at the same place till it 
broke or folded up to 200 times without breaking
5
. 
Swelling study 
Buccal patch was weighed, placed in a 1.5% agar gel 
plate and incubated at 37 ± 1 °C. At regular one-hour 
time intervals up-to 3 h, the patch was removed from 
the petri dish and excess surface water was removed 
carefully using the filter paper. The swollen patch was 
then reweighed and the swelling index was calculated. 
The experiments were carried out in triplicate and 
average values were reported
6
. 
Content uniformity 
Drug content uniformity was determined by dissolving 
the patch in 100 ml of phosphate buffer (pH 6.8) for 8 
h under occasional shaking. The 5 ml solution was 
taken and diluted with isotonic phosphate buffer pH 
6.8 up to 20 ml, and the resulting solution was filtered 
through a whatman filter paper. The drug content was 
then determined after proper dilution at 222 nm using a 
UV spectrophotometer (Shimadzu, 1800, Japan). The 
experiments were carried out in triplicate and average 
values were reported
7
. 
Ex-vivo mucoadhesive strength 
Fresh pig buccal mucosa was obtained from a local 
slaughterhouse and used within 2 h of slaughter. The 
mucosal membrane was separated by removing the 
underlying fat and loose tissues. The membrane was 
washed with distilled water at 37 °C. Bioadhesive 
strength of the patch was measured (n = 3) on a 
modified physical balance. Fresh pig buccal mucosa 
was cut into pieces and washed with isotonic 
phosphate buffer pH 6.8. A piece of buccal mucosa 
was tied to the open mouth of a glass vial, filled 
completely with isotonic phosphate buffer pH 6.8. The 
glass vial was tightly fitted in the center of a glass 
beaker filled with isotonic phosphate buffer (pH 6.8, 
37 ± 1 °C). The patch was stuck to the lower side of 
the rubber stopper with cyanoacrylate adhesive. The 
weight, in gramms, required to detach the patch from 
the mucosal surface gave the measure of 
mucoadhesive strength
8,9
. The following parameters 
were calculated from the bioadhesive strength: 
 
S. No 
 
Batch code  
Component Placebo F1 F2 F3 F4 F5 F6 F7 
          
1 Metoprolol succinate (mg) – 500 500 500 500 500 500 250 
2 Chitosan (mg) 1200 1200 1200 1200 1200 1200 1200 1200 
3 PVP K-30 (mg) – – 100 150 175 200 225 175 
4 Acetic acid (% v/v) 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
5 Propylene glycol (% v/v) – 10 10 10 10 10 10 10 
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                                          Bioadhesive strength x 9.8 
Force of adhesion (N) =  
                                                      1000 
                                             Force of adhesion 
Bond strength (N m–2) = 
                Surface area of petri dish 
 
The results are reported in Table 2 
Ex vivo mucoadhesion time 
The ex vivo mucoadhesion time was evaluated (n = 3) 
after application of the patches onto freshly cut pig 
buccal mucosa. The fresh pig buccal mucosa was fixed 
in the inner side of the beaker, above 2.0 cm from the 
bottom, with cynoacrylate glue. One side of each patch 
was wetted with one drop of isotonic phosphate buffer 
pH 6.8 and pasted to the pig buccal mucosa by 
applying a light force with a fingertip for 30 seconds. 
The beaker was filled with 500 ml of isotonic 
phosphate buffer pH 6.8 and was kept at 37 ± 1 
°C
10,11,12
. After 2 minutes, a 50 rpm stirring rate was 
applied to simulate the buccal cavity environment, and 
patch adhesion was monitored up to 12 h. The time 
required for the patch to detach from the pig buccal 
mucosa was recorded as the mucoadhesion time. The 
results are shown in Table 3. 
 
Table 2: Bioadhesive parameters of metoprolol succinate buccal patches F1 to F7 
Batch code Bioadhesive strength (g)
a
 Force of adhesion (N) Bond strength (N m
–2
) 
Placebo 20.4±  1.5 0.20 1034 
F1 11.4±  2.2 0.11 611 
F2 10.3±  1.1 0.11 549 
F3 9.1±  1.3 0.10 491 
F4 8.5±  2.1 0.09 464 
F5 3.5±  0.7 0.04 231 
F6 1.8±  0.6 0.02 136 
F7 12.2±  0.7 0.11 647 
a
 Mean ±  SD, n = 3. 
Table 3: Parameters of chitosan buccal patches of propranolol hydrochloride
a
 
a
 Mean ±  SD, n = 3. 
 
Surface pH study 
A modified method adopted to determine the surface 
pH of the patches. A combined glass electrode was 
used for this purpose. The patches were allowed to 
swell by keeping them in contact with 1 ml of distilled 
water for 2 h at room temperature, and pH was noted 
down by bringing the electrode in contact with the 
surface of the patch, allowing it to equilibrate for 1 
minute
13
. 
In vitro release 
The USP 23 rotating paddle method was used to study 
the drug release from buccal patches. The dissolution 
medium consisted of 200 ml of isotonic phosphate 
buffer pH 6.8. The release was performed at 37 ± 0.5 
°C, at a rotation speed of 50 rpm. One side of the 
buccal patch was attached to a glass disk with 
cyanoacrylate. The disk was put in the bottom of the 
dissolution vessel so that the patch remained on the 
upper side of the disk. Samples (2 ml) were withdrawn 
at pre-determined time intervals and replaced with 
fresh medium
14,15
. The samples were filtered through 
whatman filter paper with appropriate dilutions with 
phosphate buffer pH 6.8 and were assayed 
Batch 
Code 
Mass 
(mg) 
Thickness 
(mm) 
Drug 
content (%) 
Ex vivo 
 mucoadhesion 
time (min) 
Surface 
pH 
Folding 
endurance 
 
Placebo 47±  1 0.29±  0.06 0 703±  4 6.27±  0.18 206±  15 
F1 71±  1 0.49±  0.05 99.15±  0.30 298±  2 5.81±  0.16 176±  10 
F2 73±  1 0.52±  0.02 98.70±  1.35 281±  4 5.69±  0.11 175±  10 
F3 75±  1 0.54±  0.06 100.00±  0.40 269±  7 6.00±  0.12 174±  10 
F4 79±  0 0.55±  0.01 99.25±  0.18 271±  4 5.87±  0.01 162±  15 
F5 81±  1 0.56±  0.01 99.68±  0.14 189±  4 5.77±  0.11 155±  17 
F6 83±  1 0.57±  0.02 99.15±  0.59 161±  2 6.02±  0.11 149±  20 
F7 67±  1 0.41±  0.01 99.78±  0.22 428±  2 5.82±  0.03 218±  11 
Verma et al                                        Journal of Drug Delivery & Therapeutics. 2016; 6(2):14-20 17 
© 2011-16, JDDT. All Rights Reserved                                   ISSN: 2250-1177                                 CODEN (USA): JDDTAO 
spectrophotometrically at 222 nm
16
. 
In vitro buccal permeation study 
The in vitro study of metoprolol succinate   permeation 
through the pig buccal mucosa was performed using a 
diffusion cell at 37 ± 0.5 °C. Pig buccal mucosa was 
obtained from a local slaughterhouse. Freshly obtained 
pig buccal mucosa was mounted between the donor 
and receptor compartments so that the smooth surface 
of the mucosa faced the donor compartment
17
. The 
patch was placed on the mucosa and the compartments 
clamped together. The donor compartment was filled 
with 1 ml of isotonic phosphate buffer pH 6.8. The 
receptor compartment (25 ml capacity) was filled with 
isotonic phosphate buffer pH 7.4 and the 
hydrodynamics in the receptor compartment was 
maintained by stirring with a magnetic bead at 50 rpm. 
One ml sample was withdrawn at predetermined time 
intervals and analyzed for drug content at 222 nm. 
Stability in phosphate buffer  
The stability of optimized patches was tested in 
isotonic phosphate buffer (pH 6.8). Patches were 
placed in separate Petri dishes containing 5 ml of 
phosphate buffer and kept in a temperature-controlled 
oven at 37 ± 0.2 °C for 6 h
18,19
. At regular time 
intervals (0, 1, 2, 3 and 6 h), the patches were 
examined for changes in color and shape, collapse of 
the patch. Drug content was determined by appropriate 
dilution and analyzed by spectrophotometry at 222 nm. 
RESULTS AND DISCUSSION 
In the present study, buccal patches for controlled 
delivery of metoprolol succinate were developed using 
chitosan as the base matrix. The patches were prepared 
using different ratios of chitosan to PVP K-30 from 
batch F1 to F6. PVP K-30 was added to improve the 
drug release by polymer swelling, elasticity and film 
forming properties of the patches. Propylene glycol 
(10%) was added as plasticizer. On the basis of 
bioadhesive strength (8.5 ± 2.1 g) and in vitro drug 
release (82.2% in 7 h) from the buccal patches, batch 
F4 was selected for further study. Batch F7 was 
prepared from optimized batch (F4) by taking half 
quantity of the drug to study the effect of drug 
concentration in buccal formulations. 
The prepared patches were smooth in appearance, 
uniform in thickness, mass, and drug content and 
showed no visible cracks. The patches exhibited good 
folding endurance (more than 150, Table 3). Patch 
thickness ranged from 0.41 ± 0.01 to 0.57 ± 0.02 mm 
and mass ranged from 67 ± 1 to 83 ± 1 mg. Patches 
had a surface pH of 5.69 ± 0.11 to 6.02 ± 0.11. The 
drug content in the buccal patches ranged from 98.7 ± 
1.3 to 100.0 ± 0.4%, indicating the favourable drug 
loading and patches uniformity with respect to drug 
content. 
Appropriate swelling behavior of a buccal adhesive 
system is the essential property for uniform and 
prolonged release of the drug and effective 
mucoadhesion . The swelling study indicated that the 
swelling index was higher in patches containing a 
higher amount of PVP K-30. Examination of the 
patches during the dissolution studies also revealed 
that the patches showed considerable swelling, 
especially at higher concentrations of PVP K-30. The 
weak aqueous solubility of the cationic polymer 
(chitosan) limited the swelling of the patches, which 
was observed in placebo patches. Addition of the 
hydrophilic polymer PVP K-30 increased the surface 
wettability and consequently water penetration within 
the matrix. 
 
 
Figure 1:  Swelling index of buccal patches from batches F1 to F7. Mean ± SD, n = 3. 
 
Patches did not show any appreciable changes in their 
shape and form during the 3 h that they were kept on a 
1.5% agar gel plate. The optimized patch (F4) showed 
a 28.8 ± 0.8% swelling index due to water absorption 
within 3 h. Swelling behavior of patches as a function 
of time is shown in Figure 1. It was observed that 
medicated patches had a higher swelling index 
compared to plain patches. The higher swelling index 
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of medicated patches may be due to the hydrophilic 
nature of the drug, which dissolves fast when it comes 
in contact with the dissolution medium.  
Mucoadhesion may be defined as the adhesion 
between a polymer and mucus. In general, 
mucoadhesion is considered to occur in 3 major stages: 
wetting, interpenetration, and mechanical interlocking 
between mucus and polymer. The strength of 
mucoadhesion is affected by various factors such as 
molecular mass of polymers, contact time with mucus, 
swelling rate of the polymer and the biological 
membrane used in the study. In this study, pig buccal 
mucosa was used as biological membrane. Plain 
patches showed higher mucoadhesive strength (20.4 ± 
1.5 g) than medicated patches. The patch containing 10 
mg of drug (F7) showed higher bioadhesive strength 
compared to 20 mg of drug (F1 to F6). Incorporation 
of PVP K-30, a water-soluble hydrophilic polymer, 
and water-soluble drug reduced significantly the 
bioadhesive strength of buccal patches. Bioadhesive 
strength of the optimized patch (F4) was found to be 
8.5 ± 2.1 g and the force of adhesion and bond strength 
were 0.0932 N and 464.82 N m
–2
, respectively. The 
important bioadhesive parameters of buccal patches 
are given in Table 2. 
In vitro release of metoprolol succinate from different 
patches is shown in Figure 2. The drug released 
increased linearly with the increasing concentration of 
PVP-K-30 from batches F1 to F6. The maximum in 
vitro release was found to be 99.2 ± 0.7% over a 
period of 7 h in batch F6, containing the highest 
amount of PVP K–30, which could be attributed to its 
high rate and extent of swelling. This finding was also 
supported by the results of swelling studies where the 
highest swelling index was also exhibited by batch F6, 
indicating that the increase in water-soluble polymer 
PVP-K30 content results in faster swelling and release 
from patches. 
 
 
Figure 2: Cumulative drug released from batches F1 to F7. Mean ± SD, n = 3. 
 
F4 patches with 20 mg of drug showed higher and 
faster drug release than patches containing 10 mg of 
drug (F7). metoprolol succinate (a water soluble drug), 
dissolves easily in a hydrated polymeric environment. 
Therefore, the higher the loading of metoprolol 
succinate, the more drug would dissolve inside the 
hydrated matrices, resulting in a higher diffusional 
driving force and faster drug release. These results 
showed that the drug and PVP K-30 have also a 
significant effect on release behaviour of the drug from 
chitosan-based matrix. The release data were analyzed 
using the well known semi-empirical Peppas equation: 
Mt /M¥ = k t
n
 
where Mt /M¥ is the fractional release of the drug, t 
denotes the release time, k represents a kinetic 
constant, incorporating structural and geometrical 
characteristics of the device, and n is the diffusional 
exponent and characterizes the type of release 
mechanism during the dissolution process. For non-
Fickian release, the value of n falls between 0.5 and 
1.0 while in the case of Fickian diffusion n = 0.5; for 
first order release (case II transport) n = 1, and for 
supercase II transport n >1. The obtained values of k, n 
and R
2
 (coefficient determination) are presented in 
Table 4.  
 
Table 4: Kinetic constant (k), release exponent (n) and determination coefficient R
2
 
          Batch 
 Peppas model  
k (% h
–1
) R
2
 n 
F1 0.1611 0.9674 0.655 
F2 0.1817 0.9869 0.673 
F3 0.1875 0.9914 0.7025 
F4 0.2011 0.9926 0.7354 
F5 0.2102 0.9941 0.7622 
F6 0.2152 0.9916 0.7810 
F7 0.1830 0.9886 0.6931 
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Figure 3: Correlation between in vitro drug release and in vitro drug permeation. 
 
The values of n were estimated by linear regression of 
log (Mt/M ) vs. log t, and were between 0.5 and 1.0, 
indicating that the release of metoprolol succinate was 
by non-Fickian diffusion. In the kinetics study, the order 
of drug release from all batches followed zero-order 
kinetics. 
The surface pH of the patches was determined in order 
to investigate the possibility of any side effects, in vivo. 
Since an acidic or alkaline pH may cause irritation to the 
buccal mucosa, we attempted to keep the surface pH as 
close to neutral as possible. The surface pH of all the 
patches (F1 to F7) was near 7 and hence, these patches 
should not cause any irritation in the buccal cavity. Ex 
vivo mucoadhesion time for the medicated patches 
varied from 161 to 428 minutes (Table 3, the plain 
patches showed longer mucoadhesion time (703 
minutes). Incorporation of PVP K-30 and the drug 
reduced significantly ex vivo mucoadhesion time of the 
patches. Optimized patches (F4) showed a 271 minutes 
mucoadhesion time on sheep buccal mucosa. 
F4 patches were characterized by moderate swelling, a 
convenient residence time as well as adequate drug 
release. These patches were subject to investigation of in 
vitro drug diffusion and stability in phosphate buffer. 
They showed 82.9% drug permeation in 7 h through pig 
buccal mucosa. Good correlation was observed between 
in vitro drug release and in vitro drug permeation with a 
correlation coefficient of 0.98 (Figure. 3). 
 
Table 5: Stability study of optimized chitosan buccal patches (batch F4) in phosphate buffer 
Sampling time (h) Thickness (mm)
a
 Diameter (mm)
a
 Drug recovered (%)
a
 
0 0.55±  0.05 15.9±  0.11 99.7±  0.2 
1 0.55±  0.07 16.0±  0.10 99.0±  0.4 
2 0.56±  0.06 16.1±  0.03 99.4±  0.4 
3 0.59±  0.01 16.2±  0.02 99.6±  0.2 
6 0.59±  0.03 16.4±  0.09 99.3±  0.3 
a
 Mean ±  SD, n = 3. 
 
Stability studies are performed in phosphate buffer 
solutions whose pH pertains to the buccal cavity. The 
stability study of optimized patches (F4) was examined 
in phosphate buffer and their appearance characteristics, 
such as color and shape, and drug content in phosphate 
buffer saliva were evaluated (Table 5). Thickness and 
diameter of patches increased to 7.3 and 3.4% owing to 
swelling in phosphate buffer in 6 h studies. No color 
changes were observed. The recovery of the drug from 
all patches was found to be 99.7 ± 0.2% indicating 
maximum utilization of the drug incorporated. 
CONCLUSIONS 
From the present investigation, one can conclude that the 
optimized buccoadhesive patches metoprolol succinate 
with the combination of chitosan and PVP K-30 can 
meet the ideal requirements for buccal devices, which 
can be a good way to bypass the extensive hepatic first 
pass metabolism. 
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